Redeye is optimistic after Medivir's Q4 report. The new programme in osteogenesis imperfecta holds significant potential and can initiate phase II directly. The VBX-1000 veterinary programme, licensed to a partner, is entering the proof-of-concept stage, which is a value inflexion point. We are analysing these opportunities and will likely increase our base case in our coming update.
LÄS MER
